Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Oxford BioMedica partners with Orchard Therapeutics
As part of the agreement, Oxford BioMedica will develop and supply lentiviral vectors used by Orchard for the manufacture of ex-vivo gene therapy products in primary immune deficiency disorders and
As part of the agreement, Oxford BioMedica will develop and supply lentiviral vectors used by Orchard for the manufacture of ex-vivo gene therapy products in primary immune deficiency disorders and
EMD Serono is the biopharmaceutical business of Merck in the US and Canada. Under the priority review program, the FDA will decide on the BLA for avelumab within
Under the terms of the purchase agreement, Patheon will acquire the site for an immaterial sum, plus the cost of associated inventory and spare parts. Patheon has also
The agreement licenses Mylan to produce and market a generic version of Bristol-Myers Squibb's DAKLINZA (daclatasvir) Tablets, 30 mg and 60 mg, for distribution in 112 low and middle
In this trial, IV meloxicam achieved the primary endpoint of a statistically significant difference in Summed Pain Intensity Difference (SPID) over the first 24 hours (SPID24), compared to
As reported in this week’s Nature Medicine, scientists based at the Cancer Research UK Manchester Institute, Manchester, UK (CRUK MI), demonstrated that genetic patterns found in blood-borne cancer
Rexista is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. The submission is
The candidate vaccine is a non-live, recombinant vaccine to help prevent shingles and its complications. The phase III clinical trial programme showed that by reducing the incidence of
This is the second and final study agreed with the U.S. Food and Drug Administration (FDA) to support the registration of liquid-frozen IMVAMUNE. The first study, a lot
The grant will fund a new clinical trial for Severe Combined Immunodeficiency caused by adenosine deaminase deficiency, commonly known as ADA-SCID or “bubble baby” disease. ADA-SCID is a